|Bid||0.00 x 1400|
|Ask||0.00 x 1000|
|Day's range||241.68 - 245.49|
|52-week range||181.36 - 349.84|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||28.34|
|Earnings date||14 Feb 2023 - 20 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||265.75|
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.
WILMINGTON, Mass., January 18, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc., a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, today announced a viral vector contract development and manufacturing organization (CDMO) partnership. Rznomics will leverage Charles River’s viral vector CDMO experience to initiate clinical development of its RNA-based anticancer gene therapy in liver cancer patients.